Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01778439
Recruitment Status : Completed
First Posted : January 29, 2013
Last Update Posted : August 11, 2020
Information provided by (Responsible Party):
Mereo BioPharma ( OncoMed Pharmaceuticals, Inc. )

Brief Summary:
This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.

Condition or disease Intervention/treatment Phase
Relapsed or Refractory Solid Tumors Drug: OMP-52M51 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
Study Start Date : February 2013
Actual Primary Completion Date : July 2016
Actual Study Completion Date : July 2016

Arm Intervention/treatment
Experimental: OMP-52M51 Drug: OMP-52M51

Primary Outcome Measures :
  1. Safety profile of OMP-52M51 in subjects with relapsed or refractory solid tumors [ Time Frame: Subjects will be assessed for DLTs from Days 0-29. Adverse events will be reported through 30 days after the last dose ]

Secondary Outcome Measures :
  1. Pharmacokinetics (PK) of OMP-52M51 in subjects with relapsed or refractory solid tumors [ Time Frame: PK analyses at various time points following the 1st and 2nd doses, immediately pre and post-dose for all subsequent doses at treatment term, every 4 weeks after discontinuation of study drug or 12 weeks ]
    Apparent half life, AUC, clearance, volume of distribution

  2. Immunogenicity [ Time Frame: Assessed at baseline, prior to each dose, at treatment termination and every 4 weeks after the discontinuation of the study drug for 12 weeks. ]
  3. Preliminary Efficacy [ Time Frame: Evaluation for response will be assessed on day 70 of study and every 8 weeks (or 9 weeks for Q3W schedule) thereafter and will be based on RECIST v1.1. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subjects must meet all of the following criteria to be eligible for the study:

  1. Age >18 years
  2. ECOG performance status <2 (see Appendix B)
  3. Solid tumor malignancy for which there is no remaining standard therapy or either refuse or are not considered to be candidates for any remaining standard therapy.
  4. Must have a tumor that is measurable or evaluable per RECIST v1.1 in the dose escalation phase. In the expansion cohort(s), subjects must have measurable disease.
  5. Subjects must have Formalin-Fixed, Paraffin-Embedded (FFPE) tissue available either archived or fresh core or punch needle biopsied at study entry (two fresh cores/punches preferred whenever possible) for determination of Notch1 pathway activation status.
  6. Must have received their last chemotherapy, biologic, radiotherapy, or investigational therapy at least 4 weeks prior to enrollment; 6 weeks if the last regimen included BCNU or mitomycin C.
  7. Subjects must have normal organ and marrow function as defined below:

    • Absolute neutrophil count >1500/mL without growth factor support in the past 7 days
    • Platelets >100,000/mL without transfusions in the past 7 days
    • Total bilirubin <1.5 X institutional upper limit of normal (ULN) (<2X ULN for subjects with Gilbert's syndrome)
    • AST (SGOT) and ALT (SGPT) <3 X institutional ULN (for subjects with hepatic involvement <5 X institutional ULN but cannot be associated with elevated bilirubin)
    • PT/INR and aPTT within 1.5 X institutional ULN
    • Creatinine <1.5 X institutional ULN OR
    • Creatinine clearance >60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal
    • Normal Ejection Fraction (>50%) on ECHO scan or MUGA
  8. Women of childbearing potential must have had a prior hysterectomy or have a negative serum pregnancy test and be using adequate contraception prior to study entry and must agree to use adequate contraception from study entry through at least 6 months after discontinuation of study drug. Men must also agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and from study entry through at least 6 months after discontinuation of study drug. Should a woman enrolled in the study or a female partner of a man enrolled in the study become pregnant or suspect she is pregnant while participating in this study or within 6 months after discontinuation of study, she should inform the Investigator immediately.
  9. Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

Subjects who meet any of the following criteria will not be eligible for participation in the study:

  1. Currently receiving any therapeutic treatment for their malignancy including other investigational agents
  2. Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors
  3. Uncontrolled seizure disorder, active neurologic disease, or active CNS involvement except for individuals who have previously-treated CNS metastases, are asymptomatic, and have no requirement for higher doses of corticosteroids (> prednisone 10mg orally per day) or anti-seizure medication for at least 4 weeks prior to first dose of study drug.
  4. History of a Grade 4 allergic reaction attributed to humanized or human monoclonal antibody therapy
  5. Significant intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  6. Pregnant women or nursing women
  7. Ongoing malignancies or malignancies in remission <3 years other than the malignancies included in this trial. Patients with history of known squamous cell skin cancers within the past 3 years will not be included in this trial. The following prior malignancies are allowable irrespective of when they occurred: in situ carcinoma of the cervix, in situ ductal breast cancer, and low-grade local bladder cancer.
  8. Subjects with known HIV infection
  9. Known bleeding disorder or coagulopathy
  10. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.
  11. Hemoptysis in excess of 2.5 mL(or one-half teaspoon) within 8 weeks of first dose of study drug.
  12. Subjects receiving heparin, warfarin, or other similar anticoagulants, except for subjects on low molecular weight heparin for DVT/PE prophylaxis. Note: Subjects may be receiving low-dose aspirin and/or non-steroidal anti-inflammatory agents.
  13. New York Heart Association Classification II, III, or IV (see Appendix D)
  14. Subjects with poorly controlled blood pressure (defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) that is not responsive to medical therapy. Subjects taking antihypertensive medications must be taking ≤2 medications to obtain this level of blood pressure control.

    NOTE: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry.

  15. Subjects with ECG evidence of ischemia or ≥Grade 2 ventricular arrhythmia, subjects who have a history of acute myocardial infarction within 6 months, or subjects with unstable angina.
  16. Subjects with known clinically significant gastrointestinal disease including, but not limited to:

    • inflammatory bowel disease
    • active peptic ulcer disease
    • known intraluminal metastatic lesion(s) with risk of bleeding
    • history of abdominal fistula, GI perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment
  17. Subjects with diarrhea at time of enrollment or have an ongoing requirement for anti diarrheal therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01778439

Layout table for location information
United States, California
University of California, San Francisco/Helen Diller Cancer Institute
San Francisco, California, United States, 94115
United States, Colorado
University of Colorado Denver -RCI-South Tower
Aurora, Colorado, United States, 80045
United States, Michigan
Karmanos Cancer Institute (KCI)
Detroit, Michigan, United States, 48201
Wayne State University/Oncology Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
OncoMed Pharmaceuticals, Inc.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: OncoMed Pharmaceuticals, Inc. Identifier: NCT01778439    
Other Study ID Numbers: 52M51-002
First Posted: January 29, 2013    Key Record Dates
Last Update Posted: August 11, 2020
Last Verified: August 2020
Keywords provided by Mereo BioPharma ( OncoMed Pharmaceuticals, Inc. ):
Phase 1
Dose escalation
relapsed or refractory
solid tumor
Additional relevant MeSH terms:
Layout table for MeSH terms